Neurological complications after intrathecal liposomal cytarabine application in patients after allogeneic haematopoietic stem cell transplantation
Liposomal cytarabine has been proven to be useful for the prevention and intrathecal treatment of neoplastic meningitis. It has no demonstrable myelosuppressive effects and may therefore be an attractive alternative for prophylaxis and treatment of the central nervous system (CNS) relapse after allo...
Gespeichert in:
| Veröffentlicht in: | Annals of hematology 2008-12, Vol.87 (12), p.1009-1012 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1012 |
|---|---|
| container_issue | 12 |
| container_start_page | 1009 |
| container_title | Annals of hematology |
| container_volume | 87 |
| creator | Hilgendorf, Inken Wolff, Daniel Junghanss, Christian Kahl, Christoph Leithaeuser, Malte Steiner, Beate Casper, Jochen Freund, Mathias |
| description | Liposomal cytarabine has been proven to be useful for the prevention and intrathecal treatment of neoplastic meningitis. It has no demonstrable myelosuppressive effects and may therefore be an attractive alternative for prophylaxis and treatment of the central nervous system (CNS) relapse after allogeneic haematopoietic stem cell transplantation (HSCT). The use of liposomal cytarabine had not been reported in HSCT recipients. We retrospectively reviewed the feasibility of liposomal cytarabine in the prophylaxis (n = 2) and treatment (n = 4) of neoplastic meningitis in a cohort of patients after allogeneic HSCT. This report focusses on neurological complications after intrathecal application of liposomal cytarabine. Mild headache was the most commonly reported adverse event. Two patients experienced sacral radiculopathy with irreversible cauda equina syndrome in one patient. Another patient progressed with pre-existing leukencephalopathy. Intrathecal liposomal cytarabine should be used very cautiously in allogeneic HSCT recipients with a history of CNS complications potentially involving cerebral-spinal fluid circulation, since significant neurotoxicity was observed in patients with extensive CNS-directed pre-treatment. The feasibility and safety of liposomal cytarabine in HSCT recipients has to be evaluated in a prospective study. |
| doi_str_mv | 10.1007/s00277-008-0546-0 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_219271109</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1896204081</sourcerecordid><originalsourceid>FETCH-LOGICAL-c393t-c74ecd5052af065b0a47835598562b9279bc9a06e51695f2dbb9e2d911abf22a3</originalsourceid><addsrcrecordid>eNp9kc9u1DAQxi0EosvCA3CBiHvo2ImT-Igq_lSq6IH2bE28k60rxw6299Dn4IXxNgu91RfPaL7fN9J8jL3n8JkD9OcJQPR9DTDUINuuhhdsw9tGlG5oX7INqEbVsrwz9ialewAuhla8Zmd86KFtBd-wPz_pEIMLe2vQVSbMiytVtsGnCqdMsbI-R8x3dJw7u4QU5qPyIWPE0XqqcPnPFHG1lIp8_oejK-bkyZrqDmnGHJZgKZc2ZZorQ85VZYFPi0OfH13eslcTukTvTv-W3X77enPxo766_n558eWqNo1qcm36lsxOghQ4QSdHwLYfGinVIDsxKtGr0SiEjiTvlJzEbhwViZ3iHMdJCGy27NPqu8Tw-0Ap6_twiL6s1IIXnvNywC3jq8jEkFKkSS_RzhgfNAd9TEGvKeiSgj6moKEwH07Gh3Gm3RNxOnsRiFWQysjvKT5tfs714wpNGDTuo0369pcA3gCX_cBBNH8BXqifzw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>219271109</pqid></control><display><type>article</type><title>Neurological complications after intrathecal liposomal cytarabine application in patients after allogeneic haematopoietic stem cell transplantation</title><source>MEDLINE</source><source>SpringerNature Journals</source><creator>Hilgendorf, Inken ; Wolff, Daniel ; Junghanss, Christian ; Kahl, Christoph ; Leithaeuser, Malte ; Steiner, Beate ; Casper, Jochen ; Freund, Mathias</creator><creatorcontrib>Hilgendorf, Inken ; Wolff, Daniel ; Junghanss, Christian ; Kahl, Christoph ; Leithaeuser, Malte ; Steiner, Beate ; Casper, Jochen ; Freund, Mathias</creatorcontrib><description>Liposomal cytarabine has been proven to be useful for the prevention and intrathecal treatment of neoplastic meningitis. It has no demonstrable myelosuppressive effects and may therefore be an attractive alternative for prophylaxis and treatment of the central nervous system (CNS) relapse after allogeneic haematopoietic stem cell transplantation (HSCT). The use of liposomal cytarabine had not been reported in HSCT recipients. We retrospectively reviewed the feasibility of liposomal cytarabine in the prophylaxis (n = 2) and treatment (n = 4) of neoplastic meningitis in a cohort of patients after allogeneic HSCT. This report focusses on neurological complications after intrathecal application of liposomal cytarabine. Mild headache was the most commonly reported adverse event. Two patients experienced sacral radiculopathy with irreversible cauda equina syndrome in one patient. Another patient progressed with pre-existing leukencephalopathy. Intrathecal liposomal cytarabine should be used very cautiously in allogeneic HSCT recipients with a history of CNS complications potentially involving cerebral-spinal fluid circulation, since significant neurotoxicity was observed in patients with extensive CNS-directed pre-treatment. The feasibility and safety of liposomal cytarabine in HSCT recipients has to be evaluated in a prospective study.</description><identifier>ISSN: 0939-5555</identifier><identifier>EISSN: 1432-0584</identifier><identifier>DOI: 10.1007/s00277-008-0546-0</identifier><identifier>PMID: 18704421</identifier><language>eng</language><publisher>Berlin/Heidelberg: Berlin/Heidelberg : Springer-Verlag</publisher><subject>Adolescent ; Adult ; Antimetabolites, Antineoplastic - administration & dosage ; Antimetabolites, Antineoplastic - adverse effects ; Central nervous system relapse ; Cohort Studies ; Cytarabine - administration & dosage ; Cytarabine - adverse effects ; Female ; Haematopoietic stem cell transplantation ; Hematology ; Hematopoietic Stem Cell Transplantation ; Humans ; Injections, Spinal ; Leukemia, Myeloid, Acute - complications ; Leukemia, Myeloid, Acute - therapy ; Liposomal cytarabine ; Liposomes ; Lymphoma - complications ; Lymphoma - therapy ; Male ; Medicine ; Medicine & Public Health ; Meningitis - complications ; Meningitis - drug therapy ; Meningitis - prevention & control ; Middle Aged ; Oncology ; Original Article ; Precursor Cell Lymphoblastic Leukemia-Lymphoma - complications ; Precursor Cell Lymphoblastic Leukemia-Lymphoma - therapy ; Retrospective Studies ; Transplantation, Homologous</subject><ispartof>Annals of hematology, 2008-12, Vol.87 (12), p.1009-1012</ispartof><rights>Springer-Verlag 2008</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c393t-c74ecd5052af065b0a47835598562b9279bc9a06e51695f2dbb9e2d911abf22a3</citedby><cites>FETCH-LOGICAL-c393t-c74ecd5052af065b0a47835598562b9279bc9a06e51695f2dbb9e2d911abf22a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00277-008-0546-0$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00277-008-0546-0$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18704421$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hilgendorf, Inken</creatorcontrib><creatorcontrib>Wolff, Daniel</creatorcontrib><creatorcontrib>Junghanss, Christian</creatorcontrib><creatorcontrib>Kahl, Christoph</creatorcontrib><creatorcontrib>Leithaeuser, Malte</creatorcontrib><creatorcontrib>Steiner, Beate</creatorcontrib><creatorcontrib>Casper, Jochen</creatorcontrib><creatorcontrib>Freund, Mathias</creatorcontrib><title>Neurological complications after intrathecal liposomal cytarabine application in patients after allogeneic haematopoietic stem cell transplantation</title><title>Annals of hematology</title><addtitle>Ann Hematol</addtitle><addtitle>Ann Hematol</addtitle><description>Liposomal cytarabine has been proven to be useful for the prevention and intrathecal treatment of neoplastic meningitis. It has no demonstrable myelosuppressive effects and may therefore be an attractive alternative for prophylaxis and treatment of the central nervous system (CNS) relapse after allogeneic haematopoietic stem cell transplantation (HSCT). The use of liposomal cytarabine had not been reported in HSCT recipients. We retrospectively reviewed the feasibility of liposomal cytarabine in the prophylaxis (n = 2) and treatment (n = 4) of neoplastic meningitis in a cohort of patients after allogeneic HSCT. This report focusses on neurological complications after intrathecal application of liposomal cytarabine. Mild headache was the most commonly reported adverse event. Two patients experienced sacral radiculopathy with irreversible cauda equina syndrome in one patient. Another patient progressed with pre-existing leukencephalopathy. Intrathecal liposomal cytarabine should be used very cautiously in allogeneic HSCT recipients with a history of CNS complications potentially involving cerebral-spinal fluid circulation, since significant neurotoxicity was observed in patients with extensive CNS-directed pre-treatment. The feasibility and safety of liposomal cytarabine in HSCT recipients has to be evaluated in a prospective study.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Antimetabolites, Antineoplastic - administration & dosage</subject><subject>Antimetabolites, Antineoplastic - adverse effects</subject><subject>Central nervous system relapse</subject><subject>Cohort Studies</subject><subject>Cytarabine - administration & dosage</subject><subject>Cytarabine - adverse effects</subject><subject>Female</subject><subject>Haematopoietic stem cell transplantation</subject><subject>Hematology</subject><subject>Hematopoietic Stem Cell Transplantation</subject><subject>Humans</subject><subject>Injections, Spinal</subject><subject>Leukemia, Myeloid, Acute - complications</subject><subject>Leukemia, Myeloid, Acute - therapy</subject><subject>Liposomal cytarabine</subject><subject>Liposomes</subject><subject>Lymphoma - complications</subject><subject>Lymphoma - therapy</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Meningitis - complications</subject><subject>Meningitis - drug therapy</subject><subject>Meningitis - prevention & control</subject><subject>Middle Aged</subject><subject>Oncology</subject><subject>Original Article</subject><subject>Precursor Cell Lymphoblastic Leukemia-Lymphoma - complications</subject><subject>Precursor Cell Lymphoblastic Leukemia-Lymphoma - therapy</subject><subject>Retrospective Studies</subject><subject>Transplantation, Homologous</subject><issn>0939-5555</issn><issn>1432-0584</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp9kc9u1DAQxi0EosvCA3CBiHvo2ImT-Igq_lSq6IH2bE28k60rxw6299Dn4IXxNgu91RfPaL7fN9J8jL3n8JkD9OcJQPR9DTDUINuuhhdsw9tGlG5oX7INqEbVsrwz9ialewAuhla8Zmd86KFtBd-wPz_pEIMLe2vQVSbMiytVtsGnCqdMsbI-R8x3dJw7u4QU5qPyIWPE0XqqcPnPFHG1lIp8_oejK-bkyZrqDmnGHJZgKZc2ZZorQ85VZYFPi0OfH13eslcTukTvTv-W3X77enPxo766_n558eWqNo1qcm36lsxOghQ4QSdHwLYfGinVIDsxKtGr0SiEjiTvlJzEbhwViZ3iHMdJCGy27NPqu8Tw-0Ap6_twiL6s1IIXnvNywC3jq8jEkFKkSS_RzhgfNAd9TEGvKeiSgj6moKEwH07Gh3Gm3RNxOnsRiFWQysjvKT5tfs714wpNGDTuo0369pcA3gCX_cBBNH8BXqifzw</recordid><startdate>20081201</startdate><enddate>20081201</enddate><creator>Hilgendorf, Inken</creator><creator>Wolff, Daniel</creator><creator>Junghanss, Christian</creator><creator>Kahl, Christoph</creator><creator>Leithaeuser, Malte</creator><creator>Steiner, Beate</creator><creator>Casper, Jochen</creator><creator>Freund, Mathias</creator><general>Berlin/Heidelberg : Springer-Verlag</general><general>Springer-Verlag</general><general>Springer Nature B.V</general><scope>FBQ</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>20081201</creationdate><title>Neurological complications after intrathecal liposomal cytarabine application in patients after allogeneic haematopoietic stem cell transplantation</title><author>Hilgendorf, Inken ; Wolff, Daniel ; Junghanss, Christian ; Kahl, Christoph ; Leithaeuser, Malte ; Steiner, Beate ; Casper, Jochen ; Freund, Mathias</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c393t-c74ecd5052af065b0a47835598562b9279bc9a06e51695f2dbb9e2d911abf22a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Antimetabolites, Antineoplastic - administration & dosage</topic><topic>Antimetabolites, Antineoplastic - adverse effects</topic><topic>Central nervous system relapse</topic><topic>Cohort Studies</topic><topic>Cytarabine - administration & dosage</topic><topic>Cytarabine - adverse effects</topic><topic>Female</topic><topic>Haematopoietic stem cell transplantation</topic><topic>Hematology</topic><topic>Hematopoietic Stem Cell Transplantation</topic><topic>Humans</topic><topic>Injections, Spinal</topic><topic>Leukemia, Myeloid, Acute - complications</topic><topic>Leukemia, Myeloid, Acute - therapy</topic><topic>Liposomal cytarabine</topic><topic>Liposomes</topic><topic>Lymphoma - complications</topic><topic>Lymphoma - therapy</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Meningitis - complications</topic><topic>Meningitis - drug therapy</topic><topic>Meningitis - prevention & control</topic><topic>Middle Aged</topic><topic>Oncology</topic><topic>Original Article</topic><topic>Precursor Cell Lymphoblastic Leukemia-Lymphoma - complications</topic><topic>Precursor Cell Lymphoblastic Leukemia-Lymphoma - therapy</topic><topic>Retrospective Studies</topic><topic>Transplantation, Homologous</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hilgendorf, Inken</creatorcontrib><creatorcontrib>Wolff, Daniel</creatorcontrib><creatorcontrib>Junghanss, Christian</creatorcontrib><creatorcontrib>Kahl, Christoph</creatorcontrib><creatorcontrib>Leithaeuser, Malte</creatorcontrib><creatorcontrib>Steiner, Beate</creatorcontrib><creatorcontrib>Casper, Jochen</creatorcontrib><creatorcontrib>Freund, Mathias</creatorcontrib><collection>AGRIS</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Annals of hematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hilgendorf, Inken</au><au>Wolff, Daniel</au><au>Junghanss, Christian</au><au>Kahl, Christoph</au><au>Leithaeuser, Malte</au><au>Steiner, Beate</au><au>Casper, Jochen</au><au>Freund, Mathias</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Neurological complications after intrathecal liposomal cytarabine application in patients after allogeneic haematopoietic stem cell transplantation</atitle><jtitle>Annals of hematology</jtitle><stitle>Ann Hematol</stitle><addtitle>Ann Hematol</addtitle><date>2008-12-01</date><risdate>2008</risdate><volume>87</volume><issue>12</issue><spage>1009</spage><epage>1012</epage><pages>1009-1012</pages><issn>0939-5555</issn><eissn>1432-0584</eissn><abstract>Liposomal cytarabine has been proven to be useful for the prevention and intrathecal treatment of neoplastic meningitis. It has no demonstrable myelosuppressive effects and may therefore be an attractive alternative for prophylaxis and treatment of the central nervous system (CNS) relapse after allogeneic haematopoietic stem cell transplantation (HSCT). The use of liposomal cytarabine had not been reported in HSCT recipients. We retrospectively reviewed the feasibility of liposomal cytarabine in the prophylaxis (n = 2) and treatment (n = 4) of neoplastic meningitis in a cohort of patients after allogeneic HSCT. This report focusses on neurological complications after intrathecal application of liposomal cytarabine. Mild headache was the most commonly reported adverse event. Two patients experienced sacral radiculopathy with irreversible cauda equina syndrome in one patient. Another patient progressed with pre-existing leukencephalopathy. Intrathecal liposomal cytarabine should be used very cautiously in allogeneic HSCT recipients with a history of CNS complications potentially involving cerebral-spinal fluid circulation, since significant neurotoxicity was observed in patients with extensive CNS-directed pre-treatment. The feasibility and safety of liposomal cytarabine in HSCT recipients has to be evaluated in a prospective study.</abstract><cop>Berlin/Heidelberg</cop><pub>Berlin/Heidelberg : Springer-Verlag</pub><pmid>18704421</pmid><doi>10.1007/s00277-008-0546-0</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0939-5555 |
| ispartof | Annals of hematology, 2008-12, Vol.87 (12), p.1009-1012 |
| issn | 0939-5555 1432-0584 |
| language | eng |
| recordid | cdi_proquest_journals_219271109 |
| source | MEDLINE; SpringerNature Journals |
| subjects | Adolescent Adult Antimetabolites, Antineoplastic - administration & dosage Antimetabolites, Antineoplastic - adverse effects Central nervous system relapse Cohort Studies Cytarabine - administration & dosage Cytarabine - adverse effects Female Haematopoietic stem cell transplantation Hematology Hematopoietic Stem Cell Transplantation Humans Injections, Spinal Leukemia, Myeloid, Acute - complications Leukemia, Myeloid, Acute - therapy Liposomal cytarabine Liposomes Lymphoma - complications Lymphoma - therapy Male Medicine Medicine & Public Health Meningitis - complications Meningitis - drug therapy Meningitis - prevention & control Middle Aged Oncology Original Article Precursor Cell Lymphoblastic Leukemia-Lymphoma - complications Precursor Cell Lymphoblastic Leukemia-Lymphoma - therapy Retrospective Studies Transplantation, Homologous |
| title | Neurological complications after intrathecal liposomal cytarabine application in patients after allogeneic haematopoietic stem cell transplantation |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T21%3A40%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Neurological%20complications%20after%20intrathecal%20liposomal%20cytarabine%20application%20in%20patients%20after%20allogeneic%20haematopoietic%20stem%20cell%20transplantation&rft.jtitle=Annals%20of%20hematology&rft.au=Hilgendorf,%20Inken&rft.date=2008-12-01&rft.volume=87&rft.issue=12&rft.spage=1009&rft.epage=1012&rft.pages=1009-1012&rft.issn=0939-5555&rft.eissn=1432-0584&rft_id=info:doi/10.1007/s00277-008-0546-0&rft_dat=%3Cproquest_cross%3E1896204081%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=219271109&rft_id=info:pmid/18704421&rfr_iscdi=true |